Sai Life Sciences Ltd
Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]
- Market Cap ₹ 17,966 Cr.
- Current Price ₹ 860
- High / Low ₹ 943 / 635
- Stock P/E 73.6
- Book Value ₹ 102
- Dividend Yield 0.00 %
- ROCE 14.0 %
- ROE 11.0 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Stock is trading at 8.42 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 7.86% over last 3 years.
- Working capital days have increased from 37.8 days to 66.4 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 1,911 | |
| 520 | 558 | 593 | 743 | 1,048 | 1,178 | 1,285 | 1,411 | |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 500 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% | 26% |
| 6 | 18 | 27 | 28 | 27 | 29 | 35 | 39 | |
| Interest | 24 | 22 | 33 | 54 | 81 | 88 | 78 | 67 |
| Depreciation | 44 | 55 | 80 | 90 | 99 | 119 | 139 | 145 |
| Profit before tax | 113 | 109 | 82 | 10 | 16 | 109 | 228 | 327 |
| Tax % | 35% | 30% | 25% | 36% | 39% | 24% | 25% | |
| 73 | 76 | 61 | 6 | 10 | 83 | 170 | 244 | |
| EPS in Rs | 8.16 | |||||||
| Dividend Payout % | 0% | 0% | 0% | 1,116% | 676% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 25% |
| TTM: | 16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 229% |
| TTM: | 107% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 8% |
| Last Year: | 11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 |
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 |
| 249 | 304 | 637 | 752 | 933 | 928 | 352 | |
| 247 | 312 | 318 | 527 | 358 | 359 | 665 | |
| Total Liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 |
| 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
| 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | |
| Total Assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 129 | 116 | -36 | 105 | 219 | 263 | 314 | |
| -158 | -262 | -260 | -102 | -99 | -191 | -536 | |
| 268 | -4 | 296 | 72 | -201 | -95 | 301 | |
| Net Cash Flow | 239 | -150 | -1 | 75 | -80 | -24 | 79 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 99 | 102 | 85 | 64 | 76 |
| Inventory Days | 86 | 79 | 127 | 179 | 121 | 72 | 93 |
| Days Payable | 207 | 258 | 230 | 279 | 180 | 113 | 253 |
| Cash Conversion Cycle | 1 | -43 | -4 | 2 | 25 | 22 | -83 |
| Working Capital Days | 55 | 24 | 62 | 42 | 36 | 12 | 66 |
| ROCE % | 13% | 9% | 3% | 6% | 11% | 14% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 2d
-
Corrigendum To The Notice Of The 26Th Annual General Meeting.
3 Sep - Corrigendum clarifies MD/CEO Krishnam Raju's PLI target 3.25–3.5% of PAT; AGM on September 11, 2025.
-
Company -Updates
3 Sep - Response regarding MD & CEO Krishnam Raju re-appointment and PLI computation; estimated PLI INR 26.5–28.6 Mn.
-
Company-Updates
2 Sep - Seeks AGM approval to reappoint MD/CEO, remuneration up to INR 32 crore; responds to proxy advisors; appoints secretarial auditor.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 30 Aug
Concalls
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Feb 2025TranscriptNotesPPT REC
Business Overview:[1]
a) SLS is a Hyderabad-based contract research development and manufacturing organisation in the pharmaceutical sector with a significant presence in regulatory markets of US and Europe.
b) It offers integrated services across the pharmaceutical lifecycle from discovery services to development and manufacturing of new chemical entities to global innovator pharmaceutical and biotechnology companies.
c) In FY24, company has completed
200+ discovery programmes and 40+ programmes have advanced to clinical
phases.
d) SLS has a fully integrated in-house
synthetic and medicinal chemistry, drug metabolism, biology, pharmacokinetics
and toxicology.
e) In terms of therapy, they have worked in oncology and other key therapy areas include central nervous system, inflammation and anti
virals.
f) SLS provides its services to 17 out of the top 20 global pharmaceutical companies and several biotechnology companies.